|
US5030719A
(en)
|
1986-08-28 |
1991-07-09 |
Teijin Limited |
Cytotoxic antibody conjugates and a process for preparation thereof
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US8236308B2
(en)
*
|
2005-10-11 |
2012-08-07 |
Micromet Ag |
Composition comprising cross-species-specific antibodies and uses thereof
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
US8822645B2
(en)
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
|
MX2012002651A
(es)
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
CA2955947A1
(en)
*
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
IL300408B2
(en)
|
2015-01-20 |
2025-11-01 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
|
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Cytomx生物製藥公司 |
抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
|
|
BR112017023872A2
(pt)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
CN110072890B
(zh)
|
2016-11-03 |
2022-11-29 |
百时美施贵宝公司 |
可活化的抗ctla-4抗体及其用途
|
|
JP2020511130A
(ja)
|
2017-03-09 |
2020-04-16 |
サイトメックス セラピューティクス インコーポレイテッド |
Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
US11220544B2
(en)
|
2017-07-14 |
2022-01-11 |
Cytomx Therapeutics, Inc. |
Anti-CD166 antibodies and uses thereof
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
|
|
CN111212853A
(zh)
|
2017-08-30 |
2020-05-29 |
西托姆克斯治疗公司 |
可活化的抗cd166抗体及其使用方法
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
US20200405890A1
(en)
|
2018-02-21 |
2020-12-31 |
Cytomx Therapeutics, Inc. |
Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
|
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
|
CN112005304A
(zh)
|
2018-03-20 |
2020-11-27 |
西托姆克斯治疗公司 |
用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
|
|
KR20200142525A
(ko)
*
|
2018-04-05 |
2020-12-22 |
노파르티스 아게 |
암에 대한 삼중특이성 결합 분자 및 이의 용도
|
|
US20210324088A1
(en)
|
2018-05-02 |
2021-10-21 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
TWI897855B
(zh)
|
2018-10-26 |
2025-09-21 |
美商免疫遺傳股份有限公司 |
E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
|
|
BR112021008526A2
(pt)
|
2018-11-02 |
2021-08-10 |
Cytomx Therapeutics, Inc. |
anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
JP2022512124A
(ja)
|
2018-12-06 |
2022-02-02 |
シートムエックス セラピューティクス,インコーポレイテッド |
マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
|
|
WO2020176672A1
(en)
|
2019-02-26 |
2020-09-03 |
Cytomx Therapeutics, Inc. |
Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
|
|
WO2020236679A1
(en)
|
2019-05-17 |
2020-11-26 |
Cytomx Therapeutics, Inc. |
Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
|
|
US20220306745A1
(en)
|
2019-06-13 |
2022-09-29 |
Cytomx Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
|
|
WO2020252358A1
(en)
|
2019-06-13 |
2020-12-17 |
Cytomx Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
|
|
EP4034171A1
(en)
|
2019-09-23 |
2022-08-03 |
Cytomx Therapeutics Inc. |
Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
|
|
TWI841790B
(zh)
*
|
2019-09-30 |
2024-05-11 |
大陸商和鉑醫藥(上海)有限責任公司 |
靶向cd3的抗體、雙特異性抗體及其用途
|
|
AU2021206218A1
(en)
|
2020-01-06 |
2022-07-07 |
Cytomx Therapeutics, Inc. |
Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
|
|
WO2021207657A1
(en)
|
2020-04-09 |
2021-10-14 |
Cytomx Therapeutics, Inc. |
Compositions containing activatable antibodies
|
|
AU2021254283B2
(en)
|
2020-04-10 |
2025-12-11 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|